ArticleScientific reports2025
In vitro assessment of an antimicrobial peptide against Acinetobacter baumannii persister cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- Community matters: stress tolerance and survival ofFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of multidrug-resistant and persister cell populations of Acinetobacter baumannii (A. baumannii) poses a significant threat in healthcare settings, highlighting the need for novel therapeutic strategies. This study investigates a specifically designed antimicrobial peptide and its potential activity against this pathogen. Using advanced bioinformatics, a 20-amino acid antimicrobial peptide was designed and synthesized. The peptide’s efficacy was evaluated in vitro through MIC assays against A. baumannii, along with assessments of its effects on persister cells, biofilm formation, and gene expression (pmrB and lasI) using quantitative PCR. The designed peptide exhibited a potent MIC value of 64 µg/mL, reducing persister cell populations of A. baumannii by 75% within 24 h (p < 0.0001). It significantly inhibited biofilm formation, with OD reductions of up to 5.4 log at 64 µg/mL (p < 0.0001). Real-time PCR analysis revealed a 6.2-fold upregulation of pmrB and 3.7-fold upregulation of lasI after 24 h (p < 0.0001), indicating bacterial adaptive responses. The antimicrobial peptide demonstrated strong antibacterial and antibiofilm activity against A. baumannii, though with moderate cytotoxicity (8–17% reduction in cell viability). These findings suggest a promising avenue for developing novel antimicrobial strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.